In the past five years, 477 
toxin, the most potent biological toxin known to humans, is a life-threatening illness. The toxin exerts its paralytic effect by rapidly and irreversibly binding to the presynaptic cholinergic nerve terminal where it is internalised and disrupts calcium ion influx. This interferes with the release of acetylcholine from the presynaptic terminal, causing weakness. When absorbed into the systemic circulation, the toxin may produce generalised weakness, but it has a primarily local effect when injected directly into a muscle. In 1973, Dr Alan Scott, from the Smith-Kettlewell Eye Research Foundation in San Francisco, used botulinum toxin for treatment of strabismus in primates and eight years later he reported the results of botulinum toxin treatment in humans. 4 Botulinum toxin has since been tried in a variety of extraocular muscle and neurological problems." '5 We previously demonstrated in a doubleblind, placebo controlled trial that botulinuim toxin injections provide effective relief for patients with blepharospasm and possibly other focal dystonias."5 We report the results of a long-term, prospective trial of botulinum toxin treatment in 477 patients with a variety of focal dystonias and other involuntary movements.
Materials and methods Patients and assessments
To be included in the study, the patients must have had a disabling dystonia or hemifacial spasm despite optimum pharmacological therapy, surgery, or both. All patients gave a written informed consent approved by the Institutional Review Boards for Human Research of Baylor College of Medicine and The Methodist Hospital. After a complete neurological evaluation, the patients were videotaped according to a standard protocol. With the exception of nine patients with tardive dystonia and 18 patients with hemifacial spasm, all other patients had idiopathic dystonia. Patients with spasmodic dysphonia due to laryngeal dystonia had flexible fibreoptic video laryngoscopy to exclude vocal fold pathology and tremor. When the contracting muscles in patients with cervical dystonia could not be identified by inspection and palpation, electromyography (EMG) of the neck muscles was used to select the most appropriate muscles for injection.
The severity of dystonia and hemifacial spasm was rated on a 0 to 4 scale (0 = no spasm; 1 = mild, barely noticeable; 2 = mild, without functional impairment; 3 = moderate spasm, moderate functional impairment; 4 = severe, incapacitating spasm). Furthermore, the patients were instructed to rate and record the degree of their spasm in a daily diary."3 "Latency" was defined as the interval (in days) between the injection and the first sign of improvement following the injection. "Peak effect", the maximum benefit obtained from the injection, was determined after a careful review of the patient's diary, an interview of a spouse or friends, and by the patient's own perception of response. The "peak effect" was rated on a 0 to 4 scale (0 = no effect; 1 = mild improvement; 2 = moderate improvement, but no change in function; 3 = moderate improvement in severity and function; 4 = marked improvement in severity and function). "Global rating" was used as a measure of overall response and was defined as the peak effect score minus one point if the injection was associated with mild or moderate complications and two points if associated with severe or disabling complications. The "maximum" duration of improvement was the number of weeks during which the patients experienced "peak effect"; "total" duration was the entire period (in weeks) after the injection during which the patients noted any improvement. The at the time of injection. The potency is expressed in units, where one unit (U) represents the estimated LD50 for mice, approximately 0-4 ng of the protein toxin. The lethal dose in juvenile monkeys is about 40 U/kg of body weight which, when extrapolated, is approximately fifty times the average dose injected for the treatment of focal dystonia. The diluted solution was drawn into a tuberculin syringe and the toxin was injected with a 0-5 inch 30 gauge needle into superficial muscles and with a 1-5 inch 22 gauge needle into deep muscles. The dilutions were identified for each patient; 10 U/0 1 ml was used for small muscles such as the eyelids and vocal folds, and 20 U/0-1 ml was used for doses greater than 25 U per site.
At the beginning of the study there were no published guidelines; the dose therefore for each muscle was determined empirically. Low doses were used initially, particularly for small muscles, and the dose was titrated at subsequent visits depending on the patient's response after the previous injection. As we gained more experience, we adopted the following dose schedule for initial injection: 5 U for each eyebrow, 12 5 U for each eyelid, 50 U for each masseter, 20 U for other facial muscles, 100 U for neck or shoulder muscles, 30 U for one vocal fold (only one vocal fold was injected in a single visit), 25 U for forearm and 100 U for distal leg muscles.
Injection technique
With the patient in a supine position, the eyelids and eyebrows were cleaned with alcohol and the toxin was injected medially and laterally into the pretarsal orbicularis oculi, avoiding the superior oblique and the levator palpebrae muscles to prevent diplopia and ptosis respectively (fig 1) . The masseter, temporalis and submental or suprahyoid (digastric, geniohyoid, and mylohyoid) muscles were also injected when the patient was in a supine position. Other muscles were identified by palpation or by EMG and were injected with the patient in a sitting position. Patients with torticollis usually required injections into the sternocleidomastoid muscle (SCM) responsible for turning the head to the opposite side. This was usually combined with injections to the contralateral trapezius. Patients with retrocollis needed injections into both splenius capitum muscles, whereas laterocollis was treated with injections into the ipsilateral splenius capitis, trapezius, and occasionally scalenus medius. Anterocollis usually resulted from contraction of both SCMs, but occasionally injections into the submental muscles were also needed. The total dose was distributed into the larger neck muscles in four to six injections. The left thyroarytenoid vocalis muscle complex was identified by EMG and the toxin was injected through the same teflon coated hollow monopolar needle (fig 2) . The posterior pharyngeal and pterygoid muscles were approached orally."
Hemifacial spasm was treated with local injections into the muscles which contracted most, carefully avoiding perilabial regions. Patients with distal focal dystonia, such cramp or foot dystonia, receives into the most actively contracti identified by palpation and occa EMG.
Results
We report the results of 3 806 botu injections in 477 patients treated ir (tables 1-5 and fig 3) . The duraton of submental (78 right and 79 left), temporalis at more than (eight each), and pterygoids (three right and onths). The four left). Initially, we used only 25 U per ent was 3 0. muscle, but as we gained more experience we ed from 1 9 increased the dose per masseter and temporalis eir forearm muscles to 50 U. Although the "peak effect" *6 (08) for (2 4) and the maximum response duration (7.7 duration of weeks) of the 45 patients with follow up data in )m 6-7 (5 5) (fig 3) . Only 16% of the 19 (1) 15 (1) 66 (11) 29 (4) 4 (0) 2 (0) 19 (0) 103 (13) 5 (1) 4 (1) 3 (2) (1) 3 (1) 8 (0) 9 (1) 2 (0) 4 (1) 6 (1) 2 (0) 4 (1) 6 (1) 14 (3) 22 (5) One possible reason for this long duration of improvement may be the presence of subclinical denervation, which may also account for the lower than usual dose needed for the treatment of unilateral blepharospasm associated with the hemifacial spasm. Because of the marked benefit from botulinum toxin injections, we no longer recommend microvascular facial nerve decompression for these patients except in rare cases. A detailed analysis of 30 patients who failed to improve even after several treatment visits did not reveal any clinical variables, such as age, duration of illness, previous history of surgical treatment or any other demographic data that could reliably predict the poor outcome. One possible explanation for the failure to improve after botulinum toxin injections is the presence of blocking antibodies, either as a result of previous injections or because of a previous history of botulism. While some investigators718 have found anti-botulinum toxin antibodies, particularly in those patients who have received large cumulative doses and who failed to respond, another study20 found no antibodies by either bioassay or immunoassay in a large group of patients treated with the toxin. Furthermore, the presence of blocking antibodies would not explain why, despite marked weakness and atrophy of the injected muscle, some patients fail to improve. We suspect that, in such cases, the abnormal dystonic movement or posture is due to contractions of muscles that were not injected or were not readily accessible. Another possible reason for poor response to botulinum toxin injections is the presence of secondary contractures or skeletal deformities.
Besides the development of antibodies, other potential concerns on the effects of repeated botulinum toxin injections include local spread of injectate (which could account for some of the complications due to weakness of adjacent muscles), retrograde transport ofthe toxin with eventual involvement of the spinal cord or brainstem, and the possibility of denervation supersensitivity.2122 To 24 there is so far no evidence that repeat injections of the toxin produce any serious adverse systemic effects.
Although there are many unanswered questions about this new therapy, our results suggest that botulinum toxin injection should now be regarded as the treatment of choice for disabling focal dystonia and hemifacial spasm. While the long-term effects of repeated injections of botulinum toxin are unknown, our experience indicates that the treatment is safe and that the beneficial effects seem to be maintained for at least five years.
